Tejara Capital Ltd Boosts Stake in Certara, Inc. $CERT

Tejara Capital Ltd boosted its position in Certara, Inc. (NASDAQ:CERT) by 94.9% in the 3rd quarter, Holdings Channel reports. The firm owned 273,052 shares of the company’s stock after buying an additional 132,927 shares during the quarter. Certara accounts for approximately 1.7% of Tejara Capital Ltd’s portfolio, making the stock its 19th biggest position. Tejara Capital Ltd’s holdings in Certara were worth $3,337,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Associated Banc Corp lifted its stake in shares of Certara by 9.7% during the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock worth $146,000 after acquiring an additional 1,051 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in Certara by 2.5% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock valued at $535,000 after acquiring an additional 1,136 shares during the last quarter. Versant Capital Management Inc increased its stake in Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. lifted its position in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its position in shares of Certara by 22.5% during the second quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock worth $78,000 after purchasing an additional 1,223 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Analysts Set New Price Targets

CERT has been the topic of several recent analyst reports. Rothschild Redb raised shares of Certara to a “strong-buy” rating in a research note on Friday, November 21st. KeyCorp dropped their target price on shares of Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Rothschild & Co Redburn began coverage on shares of Certara in a research note on Friday, November 21st. They set a “buy” rating and a $10.00 price target for the company. Finally, Wall Street Zen lowered Certara from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Certara presently has an average rating of “Moderate Buy” and a consensus target price of $12.58.

Certara Trading Down 5.1%

NASDAQ:CERT opened at $8.79 on Friday. The firm has a 50-day simple moving average of $9.20 and a 200-day simple moving average of $10.38. Certara, Inc. has a one year low of $8.02 and a one year high of $15.69. The firm has a market cap of $1.40 billion, a P/E ratio of 125.57 and a beta of 1.46. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $104.62 million for the quarter, compared to the consensus estimate of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same period last year, the firm earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Equities analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.